mavacamten

all catalysts(0)

nothing on the calendar yet

News(10)

• United Therapeutics' legal victory; BMS' Camzyos approved for kids
  Plus, news about United Therapeutics, MindRank, Novo, Atara Biotherapeutics, Pierre Fabre, Monte Rosa Therapeutics, Bristol Myers Squibb’s Camzyos and Skopos Bio. Nektar Therapeutics' shares drop 2…
  endpoints · 2d ago
• Stripped of AstraZeneca safety net, BMS could face ‘carnage’ if high-risk clinical trial fails
  BMS is barreling toward a clinical trial readout that an H.C. Wainwright analyst believes could contribute to the return of mergers between mega-cap drugmakers.
  biospace · 1mo ago
• ESC ‘26: Cytokinetics’ sell-off, Arrowhead’s edge and a heart drug autopsy
  At a big meeting for cardiovascular medicines, Cytokinetics and Arrowhead aimed to separate their drugs from competitors while a failed study pressured Alnylam.
  biopharma_dive · 1mo ago
• Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers
  The FDA is “willing to review” an updated submission for Capricor’s Duchenne cell therapy, its CEO said. Elsewhere, a heart drug battle spilled into court and Rigel priced the first “Protac” medicine.
  biopharma_dive · 1mo ago
• Braveheart pumps more life into biotech IPO market with $382M expected debut
  Braveheart Bio has emerged on the Nasdaq with an upsized expected initial public offering—marking the public entrance of the twenty-second biotech this year.
  biospace · 1mo ago
• Braveheart charges past expectations with $382.5M IPO to fund cardio drug from Hengrui
  Braveheart Bio has overcome its own IPO expectations, rallying $382.5 million in an upsized listing to fund its cardiovascular ambitions.
  fiercebiotech · 1mo ago
• Cardiac drug developer Braveheart banks more than $382M in IPO
  Braveheart is one of five biotechnology firms that made plans to price an IPO this week. They could collectively raise more than $1 billion from public investors.
  biopharma_dive · 1mo ago
• 5 NextGen winners who went public this year (and which ones are hiring)
  BioSpace NextGen honorees made up one-third of the U.S. biotechs that have publicly debuted in 2026. Most are looking for biopharma professionals to join their teams.
  biospace · 1mo ago
• An AstraZeneca-Bristol Myers megamerger? Wall Street isn’t thrilled.
  In fact, the former lost tens of billions of dollars in market value following reports of a potential tie-up between the pharmaceutical giants.
  biopharma_dive · 2mo ago
• Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs
  Sanofi wants to broaden the company’s productive partnership with Regeneron, its CEOs said. Elsewhere, Bristol Myers delayed two anticipated study readouts and a Shionogi-backed startup went public.
  biopharma_dive · 2mo ago